Hormonal
GLP-1 and dual/triple agonist therapies (semaglutide, tirzepatide, retatrutide) produce double-digit mean weight loss (15-24%) in clinical trials, significantly exceeding older pharmacotherapies.
If you have obesity, newer GLP-1 or dual/triple agonist medications can help you lose 15-20% of your body weight, which is significantly more than older drugs. These are taken as weekly injections (or soon, oral pills). You must discuss insurance coverage and potential side effects like nausea with your doctor, as cost and access are major hurdles.
Semaglutide and tirzepatide have set new expectations for average weight loss in randomized trials... In SURMOUNT-1, tirzepatide led to a 15%-21% loss at 72 weeks... Phase 2 data show very large mean losses (20%-24% at 48 weeks at higher doses) with broad metabolic gains [retatrutide].
Why this rating
Based on large-scale Phase 3 randomized controlled trials (STEP 1, SURMOUNT-1, Phase 2 Retatrutide).
Source
Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies
Syed S Raza et al. · Cureus · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →